Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SiVEC-IAV
- Development stage
- Preclinical
- Lead developer
- SiVec Biotechnologies
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Live Biotherapeutic Products → Microbiome Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
SiVEC-IAV is a preclinical-stage inhaled antiviral therapeutic developed by SiVec Biotechnologies for the treatment and prevention of seasonal and pandemic influenza A. It utilizes the company's proprietary BactPac™ platform, a live biotherapeutic delivery system, to deliver short hairpin RNA (shRNA) or small interfering RNA (siRNA) directly to the respiratory tract. The mechanism of action involves RNA interference (RNAi) targeting highly conserved regions of the influenza A virus genome, thereby blocking viral replication across multiple strains. This approach is designed to provide broad-spectrum protection against evolving flu viruses by silencing essential viral sequences that are less prone to mutation.
- Other names
- SiVEC-IAV™
02
Targets
Influenza A virus nucleoprotein (NP) gene RNAInfluenza A virus polymerase acidic gene RNA
Beyond the preview
Go deeper on SiVEC-IAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SiVEC-IAV.